Tasigna® International Patient Assistance Program (TIPAP)
Novartis Oncology has expanded its patient access programs to incorporate Tasigna®
(nilotinib), a potent and selective inhibitor of the Bcr-Abl protein that causes
production of cancer cells in the Philadelphia chromosome-positive chronic myeloid
leukemia (Ph+ CML)
In countries where full donation is the only appropriate path to access to Tasigna,
Novartis, in partnership with The Max Foundation, has begun to establish TIPAP to
ensure that patients can receive this valuable medication.
Full donation of Tasigna through TIPAP will be available to Glivec patients who
meet both clinical and economic criteria. Leading experts in CML around the world
have developed and published medical criteria to determine when it is appropriate
to prescribe Tasigna for particular patients. Economic eligibility for full donation
of medicine through TIPAP is consistent with criteria employed for GIPAP.
New access models will facilitate partial donation of Tasigna to other patients
in countries where full donation is not applicable.